Genprex Inc GNPX

NAS: GNPX | ISIN: US3724461047   30/04/2025
0,290 USD (+3,57%)
(+3,57%)   30/04/2025

30 april 2025 · Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting · Persbericht

29 april 2025 · Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting · Persbericht

28 april 2025 · Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma · Persbericht

24 april 2025 · Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting · Persbericht

22 april 2025 · Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings · Persbericht

26 maart 2025 · Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting · Persbericht

25 maart 2025 · Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions · Persbericht

4 maart 2025 · Genprex to Participate at BIO Europe Spring 2025 · Persbericht

9 september 2024 · Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics · Persbericht

4 september 2024 · Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes · Persbericht

3 september 2024 · Genprex to Present and Participate at Upcoming September Investor and Industry Conferences · Persbericht

15 augustus 2024 · Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials · Persbericht

14 augustus 2024 · Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer · Persbericht

13 augustus 2024 · Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers · Persbericht

8 augustus 2024 · Genprex to Present at the August Sidoti Microcap Conference · Persbericht

27 juni 2024 · Genprex Issues Stockholder Letter and Provides 2024 Corporate Update · Persbericht

30 mei 2024 · Genprex to Present at the 2024 BIO International Convention · Persbericht

14 mei 2024 · Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

13 mei 2024 · Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors · Persbericht

9 mei 2024 · Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner · Persbericht

Mijn selecties